In today’s Pharmaceutical Executive Daily, Johnson & Johnson reaches an agreement with the Trump administration while continuing its $55 billion U.S. investment plan, Bristol Myers Squibb outlines its long-term strategic focus at JPMorgan 2026, and Pfizer details its pivot from COVID-era products toward pipeline execution.